6/27/2025

Janusmed sex and gender

Janusmed sex and gender – topiramate

Janusmed Sex and Gender is a knowledge database providing information on sex and gender aspects of drug treatment. The knowledge database is primarily intended to be used by physicians and healthcare professionals. The texts are general and should not be considered as treatment guidelines. The individual patient’s physician is responsible for the patient’s drug treatment.

Back to index
C C
C C

Topiramate

Topiramate

Class : C

Show all info

Print

Contact us

  1. Vovk T, Jakovljević MB, Kos MK, Janković SM, Mrhar A, Grabnar I. A nonlinear mixed effects modelling analysis of topiramate pharmacokinetics in patients with epilepsy. Biol Pharm Bull. 2010;33:1176-82.

  2. Sachdeo RC. Topiramate Clinical profile in epilepsy. Clin Pharmacokinet. 1998;34(5):335-46.

  3. Topiramate. DailyMed [www]. US National Library of Medicine. [updated 2023-05-15, cited 2024-01-19].

  4. Topimax (topiramat). Summary of Product Characteristics. Swedish Medical Products Agency [updated 2022-05-31, cited 2024-01-19].

  5. Morrell MJ. The new antiepileptic drugs and women: efficacy, reproductive health, pregnancy, and fetal outcome. Epilepsia. 1996;37 Suppl 6:S34-44.

  6. Yoo IH, Kim W, Kim H, Lim BC, Hwang H, Chae JH et al. Factors Associated with Favorable Outcome of Topiramate Migraine Prophylaxis in Pediatric Patients. J Clin Neurol. 2017;13(3):281-286.

  7. Alberici A, Borroni B, Manelli F, Griffini S, Zavarise P, Padovani A et al. Topiramate weight loss in migraine patients. J Neurol Sci. 2009;278:64-5.

  8. Reiter E, Feucht M, Hauser E, Freilinger M, Seidl R. Changes in body mass index during long-term topiramate therapy in paediatric epilepsy patients--a retrospective analysis. Seizure. 2004;13(7):491-3.

  9. Verrotti A, Scaparrotta A, Agostinelli S, Di Pillo S, Chiarelli F, Grosso S. Topiramate-induced weight loss: a review. Epilepsy Res. 2011;95:189-99.

  10. Sedighi B, Shafiei K, Azizpour I. Topiramate-induced paresthesia is more frequently reported by migraine than epileptic patients. Neurol Sci. 2016;37(4):585-9.

  11. PRAC recommends new measures to avoid topiramate exposure in pregnancy. European Medicines Agency (EMA) [www]. [updated 2023-09-01, cited 2024-01-19].

  12. Legato MJ, editor. Principles of Gender-Specific Medicine. Academic Press Inc; 2004.

  13. Tomson T, Landmark CJ, Battino D. Antiepileptic drug treatment in pregnancy: changes in drug disposition and their clinical implications. Epilepsia. 2013;54:405-14.

  14. Statistikdatabas för läkemedel. Stockholm: Socialstyrelsen. 2022 [cited 2023-03-02.]

  1. Vovk T, Jakovljević MB, Kos MK, Janković SM, Mrhar A, Grabnar I. A nonlinear mixed effects modelling analysis of topiramate pharmacokinetics in patients with epilepsy. Biol Pharm Bull. 2010;33:1176-82.
  2. Sachdeo RC. Topiramate Clinical profile in epilepsy. Clin Pharmacokinet. 1998;34(5):335-46.
  3. Topiramate. DailyMed [www]. US National Library of Medicine. [updated 2023-05-15, cited 2024-01-19].
  4. Topimax (topiramat). Summary of Product Characteristics. Swedish Medical Products Agency [updated 2022-05-31, cited 2024-01-19].
  5. Morrell MJ. The new antiepileptic drugs and women: efficacy, reproductive health, pregnancy, and fetal outcome. Epilepsia. 1996;37 Suppl 6:S34-44.
  6. Yoo IH, Kim W, Kim H, Lim BC, Hwang H, Chae JH et al. Factors Associated with Favorable Outcome of Topiramate Migraine Prophylaxis in Pediatric Patients. J Clin Neurol. 2017;13(3):281-286.
  7. Alberici A, Borroni B, Manelli F, Griffini S, Zavarise P, Padovani A et al. Topiramate weight loss in migraine patients. J Neurol Sci. 2009;278:64-5.
  8. Reiter E, Feucht M, Hauser E, Freilinger M, Seidl R. Changes in body mass index during long-term topiramate therapy in paediatric epilepsy patients--a retrospective analysis. Seizure. 2004;13(7):491-3.
  9. Verrotti A, Scaparrotta A, Agostinelli S, Di Pillo S, Chiarelli F, Grosso S. Topiramate-induced weight loss: a review. Epilepsy Res. 2011;95:189-99.
  10. Sedighi B, Shafiei K, Azizpour I. Topiramate-induced paresthesia is more frequently reported by migraine than epileptic patients. Neurol Sci. 2016;37(4):585-9.
  11. PRAC recommends new measures to avoid topiramate exposure in pregnancy. European Medicines Agency (EMA) [www]. [updated 2023-09-01, cited 2024-01-19].
  12. Legato MJ, editor. Principles of Gender-Specific Medicine. Academic Press Inc; 2004.
  13. Tomson T, Landmark CJ, Battino D. Antiepileptic drug treatment in pregnancy: changes in drug disposition and their clinical implications. Epilepsia. 2013;54:405-14.
  14. Statistikdatabas för läkemedel. Stockholm: Socialstyrelsen. 2022 [cited 2023-03-02.]